Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONO-4538HSC in Advanced or Metastatic Solid Tumors
NCT06548217Phase 1Active, not recruiting
- Sponsor
- Ono Pharmaceutical
- Start
- May 2024
- Primary completion
- Feb 2028
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of nivolumab in solid tumor, sponsored by Ono Pharmaceutical. Primary endpoints: Dose-limiting toxicities at 28 days and Adverse event. Started May 2024; status: active, not recruiting.
02
Drugs
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06548217.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06548217.